Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 EUR | +5.20% | +4.81% | -14.76% |
Apr. 03 | Nanobiotix completes escalation portion of 2020-0123 study | CF |
Apr. 02 | Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer | MT |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix